0000000000726598

AUTHOR

Carlo Di Mario

showing 30 related works from this author

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011:current status in 37 ESC countries

2014

Item does not contain fulltext AIMS: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries. METHODS AND RESULTS: A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients admitted with STEMI during 2010 or 2011. Thirty-seven ESC countries were able to provide data from existing national or regional registries. In countries where no such registries exist, dat…

AdultMalemedicine.medical_specialtyCross-sectional studymedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]PopulationCardiologyMyocardial Infarctionacute myocardial infarction610 Medicine & healthMyocardial ReperfusionPercutaneous Coronary InterventionReperfusion therapyHumansMedicineThrombolytic TherapyIn patientHospital MortalityRegistriescardiovascular diseasesMyocardial infarctioneducationAgededucation.field_of_studybusiness.industryST elevationCoronary Care UnitsPercutaneous coronary interventionThrombolysisMiddle Agedmedicine.disease3. Good healthEuropeCross-Sectional Studiessurgical procedures operativeEmergency medicineWorkforceFemaleHuman medicineMedical emergencyCardiology and Cardiovascular Medicinebusiness
researchProduct

Temporal trends in chronic total occlusion interventions in Europe: 17626 procedures from the European Registry of Chronic total occlusion

2018

Background: The study focuses on the evolution of practice, procedural outcomes, and in-hospital complications of chronic total occlusion percutaneous coronary intervention in Europe. Methods and Results: Data from 17 626 procedures enrolled in European Registry of Chronic Total Occlusion between January 2008 and June 2015 were assessed. The mean patient age was 63.9±10.9 years; 85% were men. Procedural success increased from 79.7% to 89.3% through the study period. Patients enrolled during the years had increasing comorbidities and lesion complexity (J-CTO score [Multicenter CTO Registry of Japan] increased from 1.76±1.03 in 2008 to 2.17±0.91 in 2015; P for trend, <0.001). Retrograde a…

medicine.medical_specialtyIn hospital mortalitybusiness.industrymedicine.medical_treatmentPsychological interventionPercutaneous coronary intervention030204 cardiovascular system & hematologyTotal occlusion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionTreatment OutcomeCoronary OcclusionEmergency medicineChronic DiseaseMedicine030212 general & internal medicineHospital MortalityCardiology and Cardiovascular Medicinebusiness
researchProduct

Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry

2016

Objectives The aim of this study was to evaluate midterm outcomes of bioresorbable vascular scaffolds (BVS) implanted in bifurcation lesions. Background BVS have emerged as an alternative to conventional metallic drug-eluting stents for the treatment of coronary complex lesions. Methods Between November 2011 and January 2014, 1189 patients underwent percutaneous coronary intervention with BVS at 10 European centers (GHOST EU registry). Of these, 289 consecutive patients (302 bifurcation lesions) treated with either single-stenting (n = 260) or double-stenting (n = 42) were evaluated. Results True bifurcations were treated in 44.7%. Intravascular ultrasound and optical coherence tomography w…

Target lesionmedicine.medical_specialtyAcute coronary syndromeeducation.field_of_studymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPopulationPercutaneous coronary interventionGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseBalloonSurgeryCoronary artery disease03 medical and health sciences0302 clinical medicineCoronary thrombosisIntravascular ultrasoundMedicineRadiology Nuclear Medicine and imaging030212 general & internal medicineCardiology and Cardiovascular MedicinebusinesseducationCatheterization and Cardiovascular Interventions
researchProduct

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac…

2017

Aims: The aim of the study was to develop a scoring model to evaluate the quality of bioresorbable vascular scaffold (BVS) implantation and determine the model's usefulness in predicting adverse cardiac events. Methods and results: The implantation technique and clinical outcomes of 1,736 lesions treated with BVS were analysed using the GHOST-EU registry. Predilation, scaffold sizing, and post-dilation (PSP) were scored according to the hazard model derived from the weight of these variables. The primary end-point was a one-year device-oriented composite endpoint (DoCE) composed of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation. Def…

Target lesionBioresorbable scaffoldmedicine.medical_specialtyAntineoplastic Agents030204 cardiovascular system & hematologyRisk AssessmentClinical research03 medical and health sciencesBlood Vessel Prosthesis ImplantationOutcome Assessment (Health Care)0302 clinical medicinePostoperative ComplicationsTheoreticalBlood vessel prosthesisModelsInternal medicineOutcome Assessment Health CaremedicineHumans030212 general & internal medicineMyocardial infarctionEverolimusAdverse effectProspective cohort studyBioresorbable scaffolds; Clinical research; Risk stratification; Antineoplastic Agents; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Everolimus; Humans; Outcome Assessment (Health Care); Retrospective Studies; Risk Assessment; Tissue Scaffolds; Models Theoretical; Postoperative Complications; Cardiology and Cardiovascular MedicineRisk stratificationRetrospective StudiesEverolimusTissue Scaffoldsbusiness.industryRetrospective cohort studyModels Theoreticalmedicine.diseaseThrombosisSurgeryBlood Vessel ProsthesisCardiologyBioresorbable scaffoldsbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Differences in patients and lesion and procedure characteristics depending on the age of the coronary chronic total occlusion

2018

Introduction: Whether duration of chronic total occlusion (CTO) affects lesion and procedural characteristics remains largely unknown. Aim: To investigate whether CTO duration influences lesion characteristics and revascularization success. Material and methods: EuroCTO Registry data on patients who had CTO percutaneous coronary intervention between January 2015 and April 2017 were analyzed. Three groups were created based on occlusion age: 3 to 6 months (n = 1415), 7 to 12 months (n = 973), > 12 months (n = 1656). Results: Patients with greater CTO duration were older (63.0 (56.0–70.0); 63.0 (56.0–71.0); 66.0 (59.0–73.0) years respectively; p < 0.001), had more 3-vessel disease (32.2…

medicine.medical_specialtyMultivariate analysismedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyRevascularizationlesion characteristicsPercutaneous coronary intervention.Lesion03 medical and health sciences0302 clinical medicineInternal medicineOcclusionMedicine030212 general & internal medicineLesion characteristicAdverse effectchronic total occlusionOriginal Paperbusiness.industrypercutaneous coronary interventionlcsh:RPercutaneous coronary interventionCollateral circulationmedicine.anatomical_structureCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessArtery
researchProduct

Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. A Global Expert Consensus Document

2019

© American Heart Association, Inc.

medicine.medical_specialtyGuiding PrinciplesSCORING SYSTEMmedicine.medical_treatmentPerforation (oil well)percutaneous coronaryRevascularizationMULTICENTER CTO REGISTRYCARDIOVERTER-DEFIBRILLATOR RECIPIENTSmethodsLONG-TERM OUTCOMESPROCEDURAL OUTCOMESPhysiology (medical)treatment outcome.INTRAVASCULAR ULTRASOUNDmedicineCOMPUTED-TOMOGRAPHYIntensive care medicineinterventionHEALTH-STATUStreatmentVENTRICULAR-ARRHYTHMIASbusiness.industrypercutaneous coronary interventionStentPercutaneous coronary interventionReentryRETROGRADE APPROACHcoronary occlusionCoronary occlusionConventional PCIoutcomeCardiology and Cardiovascular Medicinebusiness
researchProduct

Dual lumen microcatheters for recanalisation of chronic total occlusions: A EuroCTO Club expert panel report

2021

Dual lumen microcatheters (DLMC) have become indispensable tools in the setting of percutaneous coronary intervention (PCI) of chronic total occlusion (CTO). Other than allowing preservation and treatment of bifurcated coronary branches within or in the proximity of the CTO-body, they enable the use of modified parallel wiring, antegrade dissection and re-entry, collateral selection and retrograde negotiation of the distal CTO-cap. This Euro-CTO consensus document describes current DLMCs and suggests a practical guide to anatomies and techniques in which these devices are applicable.

medicine.medical_specialtyChronic coronary total occlusionOther techniquebusiness.industrymedicine.medical_treatmentLumen (anatomy)Percutaneous coronary interventionDissection (medical)medicine.diseaseTotal occlusionPanel reportPercutaneous Coronary InterventionExpert ConsensusConventional PCImedicineHumansBifurcationRadiologyCardiology and Cardiovascular MedicinebusinessHuman
researchProduct

TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds…

2016

medicine.medical_specialtyScoring systemEverolimusbusiness.industry030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patient030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldmedicine.drugJournal of the American College of Cardiology
researchProduct

Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview

2016

Coronary chronic total occlusions (CTOs) are commonly encountered in patients undergoing coronary angiography. Several observational studies have demonstrated that successful CTO revascularization is associated with better cardiovascular outcomes and enhanced quality of life (QOL). However, in the absence of randomized trials, its prognostic benefit for patients remains debated. Over the past decade, the interest of the interventional community in CTO percutaneous coronary intervention (PCI) has exponentially grown due to important developments in dedicated equipment and techniques, resulting in high success and low complication rates. Both European and American guidelines have assigned a c…

medicine.medical_specialtymedicine.medical_treatmentCoronary OcclusionTreatment OutcomeGuideline030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled trialQuality of lifelawCTO; PCIInternal medicinemedicineHumans030212 general & internal medicineIntensive care medicineCardiovascular outcome; Chronic total occlusion; Guidelines; PCI; Quality of life; Chronic Disease; Humans; Percutaneous Coronary Intervention; Quality of Life; Treatment Outcome; Coronary Occlusion; Cardiology and Cardiovascular Medicinebusiness.industryPercutaneous coronary interventionPCICardiovascular outcomeEvidence-based medicineCTOChronic total occlusionTreatment OutcomeCoronary OcclusionCoronary occlusionChronic DiseaseConventional PCIQuality of LifeCardiologyObservational studyCardiology and Cardiovascular MedicinebusinessHumanEuropean Heart Journal
researchProduct

Global Chronic Total Occlusion Crossing Algorithm

2021

© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC By-NC-ND License (http://creativecommons.org/licenses/by-nc-nd/4)

medicine.diagnostic_testAlgoritmosbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionGlobalState of the art reviewCollateral circulationTotal occlusionPercutaneous coronary interventionCatheterChronic total occlusionCoronary OcclusionIntravascular ultrasoundOcclusionAngiographyTreatment algorithmMedicineOclusão CoronáriaCardiology and Cardiovascular MedicinebusinessAlgorithmAlgorithms
researchProduct

Utility of Intravascular Ultrasound in Percutaneous Revascularization of Chronic Total Occlusions

2016

Intravascular ultrasound has been used for >20 years to guide percutaneous coronary intervention in different subsets of coronary lesions. During the last decade, the interest in percutaneous coronary intervention for chronic total occlusion (CTO) has increased dramatically, leading to high success rates. Failure of guidewire crossing is the most common reason for failed CTO attempts. Certain angiographic features, such as blunt proximal CTO cap, tortuosity, heavy calcification, and lack of visibility of path in the distal vessel, increase procedural difficulty. A better understanding of the behavior of the guidewire within the CTO segment may represent a key issue to achieve successful …

medicine.medical_specialtyPercutaneousmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologyRevascularizationTotal occlusionSettore MED/11 - Malattie Dell'Apparato Cardiovascolare03 medical and health sciences0302 clinical medicineBluntInternal medicineCTO = chronic total occlusion DES = drug-eluting stents IVUS = intravascular ultrasound MACE = major adverse cardiac event(s) PCI = percutaneous coronary interventionIntravascular ultrasoundConventional PCImedicineCardiology030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessMace
researchProduct

Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicente…

2017

The aim of this study was to report on the midterm outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD).One thousand four hundred and seventy-seven (1,477) patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centres and were included in the GHOST-EU registry. Admissions comprised 47.1% of the patients (951 BVS) with ACS, and 52.8% (1,274 BVS) with sCAD. During a median follow-up of 384 (359-460) days, patient-oriented endpoints (PoCE), inclu…

Target lesionMaleAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentInfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumans030212 general & internal medicineRegistriesAcute Coronary SyndromeAgedRetrospective StudiesTissue Scaffoldsbusiness.industryUnstable anginaIncidence (epidemiology)Percutaneous coronary interventionMiddle Agedmedicine.diseaseThrombosisTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Chronic total coronary occlusions and the Occluded Artery Trial. A critical appraisal.

2008

The OAT trial and its angiographic substudy TOSCA-2, along with a number of published commentaries, represents examples of over-interpretation of clinical study results. A study that achieved no statistically significant result for any of the study endpoints can only claim to have proven that their null hypothesis cannot be rejected. The lack of power due to a reduction of patient numbers by one third, and an unexpected low event rate, makes it not unlikely that another trial would be able to disprove the null hypothesis. These statistical facts should be accepted by the authors and commentators. Instead, the inconclusive results were interpreted in such a way that they might apply to patie…

medicine.medical_specialtybusiness.industryMyocardial Infarctionocclusions.Critical appraisalmedicine.anatomical_structureCoronary OcclusionInternal medicinemedicineCardiologyHumansChronicCardiology and Cardiovascular MedicinebusinesscoronaryRandomized Controlled Trials as TopicArteryEuroIntervention
researchProduct

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct

Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions

2017

Abstract Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinical…

Target lesionmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologymedicine.diseaseSurgeryCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineCoronary thrombosisInterquartile rangeCardiovascular agentMedicine030212 general & internal medicineMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds : a European perspective

2015

Aims Next to patient characteristics, the lack of a standardised approach for bioresorbable vascular scaffold (BVS) implantation is perceived as a potential explanation for the heterogeneous results reported so far. To provide some guidance, we sought to find a consensus on the best practices for BVS implantation and management across a broad array of patient and lesion scenarios. Methods and results Fourteen European centres with a high volume of BVS procedures combined their efforts in an informal collaboration. To get the most objective snapshot of different practices among the participating centres, a survey with 45 multiple choice questions was prepared and conducted. The results of th…

Diagnostic Imagingmedicine.medical_specialtyConsensusBest practiceMEDLINEPatient characteristicsConsensus criteriaCoronary Artery DiseaseProsthesis DesignPercutaneous Coronary InterventionPredictive Value of TestsRisk FactorsSurveys and QuestionnairesAbsorbable ImplantsmedicineHumansMedical physicsPractice Patterns Physicians'Multiple choiceBioresorbable vascular scaffoldbusiness.industryPatient SelectionSurgeryEuropeTreatment OutcomeHealth Care SurveysCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldIntravascular imagingHospitals High-Volume
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes …

2015

Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry.Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1…

MaleReoperationTarget lesionmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionAntineoplastic AgentsComorbidityCoronary Artery DiseaseAngina PectorisPercutaneous Coronary InterventionRisk FactorsInterquartile rangeInternal medicineAbsorbable ImplantsDiabetes MellitusmedicineHumansCumulative incidenceEverolimusMyocardial infarctionAcute Coronary SyndromeAgedProportional Hazards ModelsTissue Scaffoldsbusiness.industryHazard ratioPercutaneous coronary interventionDrug-Eluting StentsThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEuropeTreatment OutcomeCardiovascular DiseasesConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Effect of implantation technique on outcomes in patients receiving bioresorbable scaffolds in various clinical scenarios

2021

ABSTRACT Introduction and objectives: The PSP (pre-dilation, sizing and post-dilation) score, derived from the GHOST-EU registry, has evaluated the relationship between the implantation technique of bioresorbable scaffolds and the clinical outcomes. The objective was to perform an external validation of the PSP technique and to determine its effect on adverse cardiac events in various clinical and anatomical scenarios. Methods: Data from the REPARA registry (2230 patients) were used for external validation, whereas a common database combining REPARA and GHOST-EU (3250 patients) data was used to evaluate the effect of PSP technique in various clinical and anatomical scenarios. PSP-1 and PSP-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentRPercutaneous coronary interventionmedicine.diseaseCoronary artery diseaseeye diseasesPercutaneous coronary interventionSurgeryCoronary artery diseaseBioresorbable vascular scaffoldsBioresorbable scaffoldsmedicineMedicineIn patientCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldREC: interventional cardiology (English Edition)
researchProduct

European experience with the retrograde approach for the recanalization of coronary artery chronic total occlusions. A report on behalf of the EuroCT…

2008

Aims Recanalisation rates of coronary chronic total occlusions (CTO) remain sub-optimal. The retrograde technique was recently introduced to improve success rates. Methods and results From February 2005 until December 2007, 175 patients were treated with this technique in seven European centres by highly experienced operators: in 84 (48%) as primary strategy, in 41 (23.5%) immediately after antegrade failure and in 50 (28.5%) as a repeat procedure after previous antegrade failure. Baseline characteristics revealed a mean age 61.4 +/- 10.8 years with 29.5% and 39% of patients having diabetes and a prior history of MI, respectively. The mean occlusion duration was 50.8 months (determined in 3…

Malemedicine.medical_specialtymedicine.medical_treatmentCollateral CirculationCoronary AngiographyBalloonCoronary circulationCoronary CirculationAngioplastyOcclusionmedicineHumansMyocardial infarctionAngioplasty Balloon CoronarySeptal collaterals.Agedbusiness.industryMiddle Agedmedicine.diseaseCollateral circulationSurgeryEuropeChronic total occlusionTreatment Outcomemedicine.anatomical_structureCoronary OcclusionCoronary occlusionChronic DiseaseRetrogradeFemaleCardiology and Cardiovascular MedicinebusinessArtery
researchProduct

Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre …

2017

Background Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesi…

Target lesionMaleTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary Angiography0302 clinical medicineRisk FactorsNuclear Medicine and ImagingAbsorbable ImplantsClinical endpoint030212 general & internal medicineMyocardial infarctionRegistriesdiabetesClinical performanceGeneral MedicineMiddle AgedThrombosisbioresorbable vascular scaffoldsclinical outcomesEuropeTreatment Outcomebioresorbable vascular scaffolds; clinical outcomes; diabetes; Radiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineCardiologyFemaleRadiologyCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationProsthesis Design03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansRadiology Nuclear Medicine and imagingIn patientEverolimusAgedRetrospective Studiesbusiness.industryCoronary ThrombosisCardiovascular Agentsmedicine.diseaseSurgerybusinessCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imagi…

2014

The benefits of cardiac imaging are immense, and modern medicine requires the extensive and versatile use of a variety of cardiac imaging techniques. Cardiologists are responsible for a large part of the radiation exposures every person gets per year from all medical sources. Therefore, they have a particular responsibility to avoid unjustified and non-optimized use of radiation, but sometimes are imperfectly aware of the radiological dose of the examination they prescribe or practice. This position paper aims to summarize the current knowledge on radiation effective doses (and risks) related to cardiac imaging procedures. We have reviewed the literature on radiation doses, which can range …

Prenatal Diagnosimedicine.medical_treatmentScintigraphyImagingPregnancyRisk FactorsPrenatal DiagnosisCancer; Cardiovascular disease; Imaging; Radiation; Radiological protection; Risk; Cardiac Imaging Techniques; Cardiology; Child; Female; Heart Diseases; Humans; Informed Consent; Occupational Exposure; Pregnancy; Pregnancy Complications; Prenatal Diagnosis; Radiation Injuries; Radiation Protection; Risk Factors; Tomography X-Ray Computed; Unnecessary Procedures; Radiation Dosage; Cardiology and Cardiovascular MedicineRadiation InjurieChildTomographyRadiological protectionCardiac imagingCancerRadiationInformed Consentmedicine.diagnostic_testCardiovascular diseasePregnancy ComplicationX-Ray ComputedHeart DiseaseFemaleRadiologyCardiology and Cardiovascular MedicineHumanUnnecessary ProcedureRiskmedicine.medical_specialtyModern medicineHeart DiseasesCardiologyUnnecessary ProceduresRadiation DosageMyocardial perfusion imagingRadiation ProtectionOccupational ExposuremedicineMedical imagingHumansMedical physicsRadiation Injuriesta3126Cardiac Imaging Techniquebusiness.industryRisk FactorPercutaneous coronary interventionMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREta3121Pregnancy ComplicationsCardiac Imaging TechniquesCardiac Imaging TechniquesRadiation protectionTomography X-Ray Computedbusiness
researchProduct

Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry

2019

Abstract Objectives The aim was to establish a contemporary scoring system to predict the outcome of chronic total occlusion coronary angioplasty. Background Interventional treatment of chronic total coronary occlusions (CTOs) is a developing subspecialty. Predictors of technical success or failure have been derived from datasets of modest size. A robust scoring tool could facilitate case selection and inform decision making. Methods The study analyzed data from the EuroCTO registry. This prospective database was set up in 2008 and includes >20,000 cases submitted by CTO expert operators (>50 cases/year). Derivation (n = 14,882) and validation (n = 5,745) datasets were created to develop a …

medicine.medical_specialtyFramingham Risk Scorebusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologymedicine.diseaseCoronary artery disease03 medical and health sciencesDissection0302 clinical medicineCoronary occlusionAngioplastyOcclusionmedicine030212 general & internal medicineRadiologyDerivationCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

2020

Abstract Aims To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7–32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3–70.3; P …

MaleMyocardial Infarction030204 cardiovascular system & hematologySettore MED/110302 clinical medicineAcute myocardial infarction Cardiac care units STEMI Aged Aged 80 and over COVID-19 Female Hospitalization Humans Italy Male Middle Aged SARS-CoV-2 Betacoronavirus Coronavirus Infections Myocardial Infarction Pandemics Pneumonia ViralCase fatality rate80 and overMedicine030212 general & internal medicineMyocardial infarctionViralAged 80 and overAcute myocardial infarction; Cardiac care units; COVID-19; SARS-CoV2; STEMI; Aged; Aged 80 and over; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Betacoronavirus; Coronavirus Infections; Myocardial Infarction; Pandemics; Pneumonia ViralMiddle AgedHospitalizationItalyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanmedicine.medical_specialtyPneumonia ViralFast Track Clinical ResearchCardiac care unitsAcute myocardial infarctionSTEMI03 medical and health sciencesBetacoronavirusCardiac care unitHumansAcute myocardial infarction; COVID-19; Cardiac care units; SARS-CoV2; STEMIcardiovascular diseasesPandemicsAgedBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19Pneumoniamedicine.diseaseacute myocardial infarction; cardiac care units; COVID-19; SARS-CoV2; STEMIConfidence intervalRelative riskEmergency medicineSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARESARS-CoV2Myocardial infarction complicationsObservational studyMyocardial infarction diagnosisbusinessComplication
researchProduct

Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry : the …

2019

Objectives: The aim was to establish a contemporary scoring system to predict the outcome of chronic total occlusion coronary angioplasty. Background: Interventional treatment of chronic total coronary occlusions (CTOs) is a developing subspecialty. Predictors of technical success or failure have been derived from datasets of modest size. A robust scoring tool could facilitate case selection and inform decision making. Methods: The study analyzed data from the EuroCTO registry. This prospective database was set up in 2008 and includes >20,000 cases submitted by CTO expert operators (>50 cases/year). Derivation (n = 14,882) and validation (n = 5,745) datasets were created to develop a …

Aged 80 and overMaleDatabases FactualRisk Factorpercutaneous coronary interventionscoring systemReproducibility of Resultschronic total occlusion; coronary artery disease; percutaneous coronary intervention; scoring system; Aged; Aged 80 and over; Chronic Disease; Coronary Occlusion; Databases Factual; Europe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Predictive Value of Tests; Registries; Reproducibility of Results; Risk Assessment; Risk Factors; Treatment Failure; Decision Support TechniquesMiddle AgedRisk AssessmentDecision Support TechniquesEuropePercutaneous Coronary InterventionCoronary OcclusionPredictive Value of TestsRisk FactorsChronic DiseaseHumansFemaleRegistriesTreatment Failurechronic total occlusioncoronary artery diseaseAged
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review

2021

© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC-BY-NC-ND license.

Coronary Occlusionpercutaneous coronary interventionHumanstreatment algorithmglobalCoronary Angiographychronic total occlusionAlgorithms
researchProduct